Organic Active Ingredients TRIZ Cases

Cell-penetrating asiRNAs silence CTGF mRNA to reduce fibrosis progression without requiring organ transplantation.

A nanoliposome-microbubble conjugate encapsulates finasteride and utilizes sonoporation to penetrate the skin barrier.

Novel cyclic dinucleotides activate the STING pathway to induce endogenous cytokine production.

Biodegradable PLGA-PEG-PLGA triblock copolymers form a thermogel that solubilizes poorly water-soluble chemotherapeutics without toxic surfactants.

Administering vitamin B12 to overweight mothers reduces offspring obesity risk by correcting nutritional deficiencies that program metabolic disorders.

Antisense oligonucleotides induce exon skipping in DMD pre-mRNA to restore dystrophin expression while minimizing side effects.

Tailored cationic lipids resolve transfection efficiency versus specificity trade-offs by optimizing membrane interaction via defined structural parameters.

Hot water rinsing creates a low oxygen environment for acetaminophen composition preparation.

Enteric coating shields vitamin D3 from stomach acid degradation, resolving the trade-off between calcium absorption and compound stability.

A solid pharmaceutical lozenge utilizing a PVP and CMC polymer matrix to enable rapid transmucosal anesthetic delivery.

Segmenting the reaction into organic and aqueous phases resolves low conversion rates while simplifying purification.

Segmented wet granulation overcomes formulation constraints to produce high-DHEA tablets that fit standard contraceptive blister packs.

L-carnitine supplements decrease skeletal muscle damage and oxidative stress by enhancing fat utilization as fuel during exercise.

Segmented solid-phase synthesis controls ligand spatial distance to resolve steric hindrance and boost binding affinity.

Optimizing drug-to-antibody ratios and cleavable linkers prevents aggregation while preserving therapeutic efficacy against tumors.

Novel imidazo[1,2-a]pyrazine derivatives inhibit phosphodiesterase 10 to modulate dopamine activity.

Fine-particle crosslinked polyvinylpyrrolidone provides smooth tablet surfaces and homogeneous mixing.

Formula II derivatives antagonize the CGRP receptor to treat migraine while avoiding cardiovascular side effects linked to triptans.

Orientin, vitexin, and bergenin composition reduces amyloid fibril formation and tau accumulation to address Alzheimer's disease mechanisms.

Fused tricyclic compounds block both mTORC1 and mTORC2 signaling pathways, overcoming the limited efficacy of single-complex inhibitors in cancer treatment.

Delaying breastfeeding by five hours after solriamfetol administration reduces infant drug exposure and minimizes adverse events like agitation.

Segmenting iodine into the polymer core maintains crosslink density and simplifies synthesis, resolving trade-offs between radiopacity and structural integrity.

Formula I piperidinylcarbazoles overcome rising parasite resistance by modifying chemical structures to maintain treatment effectiveness against malaria.

Inhibitors of microRNAs 19a and 19b treat osteoporosis by blocking Sclerostin mRNA degradation, avoiding daily injection requirements.

Administering a CLEC-1 antagonist prevents immune suppression by myeloid cells, thereby enhancing anti-tumor immunity.

A dry milling process uses a liquid binding agent to produce indomethacin particles below 100 microns, preventing material caking and enhancing bioavailability.

Repurposing ponatinib resolves the contradiction between variant effectiveness and oral administration capability.

Pyrimidine dione compounds inhibit CD73 enzyme activity, blocking extracellular adenosine accumulation that suppresses anti-tumor adaptive immunity.

Fused tricyclic compounds simultaneously constrain mTORC1 and mTORC2 complexes to overcome partial inhibition limits of existing agents.

Amidopyrimidone derivatives inhibit human methionine adenosyltransferase 2A, disrupting the methionine salvage pathway to delay cancer progression.

Segmented compounds target specific sigma receptor subtypes to resolve selectivity issues in treating neurological disorders.

Segmented polymeric carriers improve in vivo half-life and persistence while minimizing cytokine production during targeted delivery.

Administering aromatic-cationic peptides to treat Alport Syndrome by targeting specific genetic deficiencies in collagen structure.

Introducing sulfonamide groups into the methyl group of galiellalactone improves STAT3 inhibitory potency while reducing side effects.

Blood eosinophil progenitor levels replace invasive endoscopies to monitor eosinophilic esophagitis disease activity.

Optimized pyrimidine-5-carboxamide compounds inhibit NNMT to improve insulin sensitivity and treat type 2 diabetes.

An amorphous pralsetinib dispersion paired with an effervescent couple overcomes low solubility and delayed dissolution to enable immediate release.

A multi-layer coating method deposits a second drug layer onto a crystalline first drug layer using selective solvents to preserve the initial drug structure.

A molecular delivery system conjugates cell-penetrating peptides to oligonucleotides for efficient trans-membrane transport.

Methylated and acetylated scutellarin derivative improves solubility and bioavailability.

miRNA-17-92 cluster oligonucleotides induce cardiomyocyte proliferation, restoring regenerative capacity and improving cardiac function in adult hearts.

Stepwise synthesis of thiolated mPEG-PLA-CS-MBI nanoparticles resolves weak hydrophobic drug reactions by enabling sustained release through disulfide bonding.

Small molecule compounds block vascular endothelial growth factor binding to neuropilin receptor 1, preventing SARS-CoV-2 viral entry into cells.

Heterocyclic compounds modulate STING activity to regulate type I interferon, resolving inadequate immune control in autoimmune diseases and cancers.

HERCEPTIN-maytansinoid conjugates combine antibody targeting with cytotoxic maytansinoids to deliver potent therapeutic agents directly to tumor cells.

A spray-dried powder composition containing phospholipids and lipophilic extracts enables stable solid formulations.

Replacing PEG with polyoxazoline lipids stabilizes mRNA carriers while eliminating accelerated blood clearance and immune activation.